Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 50.5 EUR 0.2% Market Closed
Market Cap: 10.4B EUR
Have any thoughts about
Recordati Industria Chimica e Farmaceutica SpA?
Write Note

Net Margin
Recordati Industria Chimica e Farmaceutica SpA

18.7%
Current
20%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.7%
=
Net Income
423.1m
/
Revenue
2.3B

Net Margin Across Competitors

Country IT
Market Cap 10.4B EUR
Net Margin
19%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.1B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 348B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 150.1B USD
Net Margin
7%
No Stocks Found

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Market Cap
10.4B EUR
Industry
Pharmaceuticals

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

REC Intrinsic Value
58.25 EUR
Undervaluation 13%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.7%
=
Net Income
423.1m
/
Revenue
2.3B
What is the Net Margin of Recordati Industria Chimica e Farmaceutica SpA?

Based on Recordati Industria Chimica e Farmaceutica SpA's most recent financial statements, the company has Net Margin of 18.7%.